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Correction to: Scientific Reports https://doi.org/10.1038/s41598-018-23423-1, published online 22 March 2018
This Article contains typographical errors.
In the Results section under subheading ‘Rifampin Binding in M. leprae RNAP’,
“As the activity of rifampin relies on its ability to induce a steric clash with the 5′-ribonucleotide, mutations that 
influence its orientation in the binding pocket might lead to reduction in these steric clashes resulting inse-
set_name sele rifampin resistance.”
should read:
“As the activity of rifampin relies on its ability to induce a steric clash with the 5′-ribonucleotide, mutations that 
influence its orientation in the binding pocket might lead to reduction in these steric clashes resulting in rifampin 
resistance.”
In the Discussion section,
“Lepromatous leprosy (LL) is characterized by high bacillary loads and low M. leprae specific cell-mediated 
immune responses32 in the host, increasing likelihood of the presence of bacterial persisters post-treatment which 
may adopt to rifampin by inducing point mutations with the RRDR.”
should read:
“Lepromatous leprosy (LL) is characterized by high bacillary loads and low M. leprae specific cell-mediated 
immune responses32 in the host, increasing likelihood of the presence of bacterial persisters post-treatment which 
may adapt to rifampin by inducing point mutations within the RRDR.”
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License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
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